Clinical Oversight Review Board (CORB) Criteria for Prescribing

Sacituzumab Govitecan (Trodelvy)


Non-Formulary **sacituzumab govitecan (Trodelvy)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

<u>Initiation (new start) criteria</u>: Non-formulary **sacituzumab govitecan (Trodelvy)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of triple negative, metastatic breast cancer
- Received two or more prior chemotherapy regimens in the advanced setting

kp.org

Revised: 12/10/20 Effective: 02/18/21





All plans offered and underwritten by